Young Joon Byun

List of Publications by Year
in descending order

18 papers	217 citations

933447

10 h-index	

1058476

14 g-index	

18 all docs	18 docs citations	18 times ranked	308 citing authors

#	ARTICLE	IF	CITATIONS
1	Urinary cell‑free microRNA biomarker could discriminate bladder cancer from benign hematuria. International Journal of Cancer, 2019, 144, 380-388.	5.1	30
2	Collagen typeÂVIâ€Î±1 and 2 repress the proliferation, migration and invasion of bladder cancer cells. International Journal of Oncology, 2021, 59, .	3.3	21
3	Identification of differentially expressed miRNAs and miRNA-targeted genes in bladder cancer. Oncotarget, 2018, 9, 27656-27666.	1.8	20
4	<i>CDC6</i> mRNA Expression Is Associated with the Aggressiveness of Prostate Cancer. Journal of Korean Medical Science, 2018, 33, e303.	2.5	19
5	Methylation Signature for Prediction of Progression Free Survival in Surgically Treated Clear Cell Renal Cell Carcinoma. Journal of Korean Medical Science, 2019, 34, e144.	2.5	17
6	Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness. Clinical Genitourinary Cancer, 2017, 15, 450-454.	1.9	14
7	Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer. Investigative and Clinical Urology, 2021, 62, 340.	2.0	14
8	Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Nonâ€"Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, e704-e711.	1.9	12
9	A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 237.e21-237.e29.	1.6	12
10	Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 86-96.	1.6	11
11	A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncology Letters, 2020, 19, 476-486.	1.8	9
12	Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 274-280.	1.9	8
13	A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone. Investigative and Clinical Urology, 2020, 61, 411.	2.0	7
14	Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression. International Journal of Molecular Sciences, 2021, 22, 12756.	4.1	7
15	ZNF492 and GPR149 methylation patterns as prognostic markers for clear cell renal cell carcinoma: Arrayâ€'based DNA methylation profiling. Oncology Reports, 2019, 42, 453-460.	2.6	6
16	Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer. Prostate International, 2022, 10, 1-6.	2.3	5
17	Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone. Investigative and Clinical Urology, 2022, 63, 238.	2.0	3
18	Expression of RPL9 predicts the recurrence of non-muscle invasive bladder cancer with BCG therapy. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	2